The rationale for a type 17 signature in the pathogenesis of <SpA. class="ui text orange" data-tooltip="Disease"><SpA. class="ui text orange" data-tooltip="Disease">spondyloarthritisSpA.>SpA.> (<SpA. class="ui text orange" data-tooltip="Disease">SpASpA.>) has been increasing and being ratified in studies recently. <SpA. class="ui text teal" data-tooltip="Gene">IL-7SpA.> is a cytokine whose ability to stimulate IL-17 production in both innate and adaptive immunity cells has made it a promising target not only for a better understanding of the disease as well as an important potential therapeutic target in <SpA. class="ui text green" data-tooltip="Species">patientsSpA.> with <SpA. class="ui text orange" data-tooltip="Disease">SpASpA.>.